Gum Disease Could Render Cardiovascular Medication Ineffective
Posted on: Friday, 6 January 2006, 21:00 CST
The contraction of an infectious gum disease could influence the effectiveness of antibiotics used for the prevention of recurrent cardiovascular events, according to scientists at the University of Helsinki.
The study showed that a three-month course of treatment with antibiotics could decrease the recurrence of cardiovascular events in patients without periodontitis, an infection of the gingiva or gums, while the medication was found to have no effect in patients with periodontitis.
This is the first time dental infections have been linked to the effectiveness of long-term treatment with antibiotics designed to prevent myocardial infarcts.
According to the results, long-term antibiotic medication would prevent myocardial infarcts in patients that do not have periodontitis, or related signs of inflammation such as disease-causing bacteria or antibodies to those bacteria.
Periodontitis appears to be such a significant chronic infection that the effect of antibiotic treatment in preventing cardiovascular events is lost in patients that suffer from it. During one year of observation, patients with no signs of periodontitis were more likely to avoid new cardiovascular events. This difference was particularly pronounced in patients under the age of 65: 90% of non-periodontitis subjects completed the year without a new cardiovascular event, compared with only 64% of those with periodontitis and 50% of those without teeth.
In patients under the age of 65, periodontitis may cause a fivefold increase in the risk of recurrent acute cardiovascular events in comparison with healthy people.
The researchers examined 141 patients who were hospitalized for acute cardiovascular events. The double-blind trial involved registering the recurrence of new cardiovascular events over one year and measured the presence of Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis using saliva and serum samples.
Source: Datamonitor
Related Articles
- VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients
- Research Finds Higher Drug Co-Pays Discourage Patients From Starting Treatment
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Number of Patients Treated With an Antibiotic for MRSA Within U.S. Acute Care Hospitals Increased 8 Percent From 2006 to 2007
- CapMed Launches Second Phase of Personal Health Record (PHR) Project With Cardiovascular Patients in North Carolina
- VIRxSYS Presents Update On HIV Gene Therapy Clinical Trial At ICAAC; Study Shows No Adverse Side Effects After More Than 65 Patient Years of Treatment
- St. Jude Medical Announces Agreement With LUMEDX To Manage Cardiovascular Patient Data
- Study Finds a Relationship Between Periodontal (Gum) Treatment
- Thrombocytopenia in Cardiovascular Patients*: Diagnosis and Management
- Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients
 |
 |
User Comments (0)
RSS Feeds